Abstract
The liver metastasis is the main death cause of the colorectal cancer. About 20 % of patients at first diagnosis have liver metastasis; besides, in the follow-up after colorectal cancer operation, there will be 20–45 % of patients with liver metastasis. This means that at least half of patients with colorectal cancer will have liver metastasis during the development of the colorectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastasis. Onkologie 2007;30: 637–43.
Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with cetuximab/FOLFOX-4 in the treatment of mCRC epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006;17:450–6.
Peeters M, Raoul JL, van Laethem JL, Rougier P, Brezault C, Husseini F, Cals L, Zubel A, Vedovato JC. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer (Suppl). 2005;3:188.
van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Slides presented at ASCO 2007 annual meeting, Chicago, 15 Jun 2007. Abstract 4000.
Tabernero J, van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, van Laethem JL, Soulié P, Casado E, Verslype C, Sastre J, Tortora G, Ciardiello F, Kisker O, de Gramont A. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;33:5225–32.
Adam R, Aloia T, Levi F. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25(29):4593–602.
Gruenberger B, Tamandl D, Schueller J. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26(11):1830–5.
Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009;7:1033–8
Berry SR, Van Cutsem E, Kretzschmar A. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. J Clin Oncol. 2008;26(Suppl; abstr 4025).
Cassidy J, Cunningham D, Berry SR. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): first BEAT and NO16966. J Clin Oncol. 2008;26(Suppl; abstr 4022).
Bechstein WO, Lang H, Köhne C, et al. Resectability and agreement between surgeons: review of CT and MR scan of the CELIM study: (multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol. 2009;27:15s(Suppl; abstr 4091).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Dordrecht and People's Medical Publishing House
About this chapter
Cite this chapter
Zhou, J., Shen, L. (2017). Targeted Therapy of Colorectal Cancer Liver Metastasis. In: Qin, X., Xu, J., Zhong, Y. (eds) Multidisciplinary Management of Liver Metastases in Colorectal Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7755-1_17
Download citation
DOI: https://doi.org/10.1007/978-94-017-7755-1_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7753-7
Online ISBN: 978-94-017-7755-1
eBook Packages: MedicineMedicine (R0)